Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew P Grigg

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Haematologica|October 5, 2023
Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1Howland E Crosswell, Ann S LaCasce, Nancy L Bartlett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2022
Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration CohortsPaul M Barr, Alessandra Tedeschi, William G Wierda, et al.
Pathology|March 6, 2021
Myeloid somatic mutation panel testing in myeloproliferative neoplasmsDavid M Ross, Candice Thomson, Nada Hamad, et al.
The New England Journal of Medicine|July 8, 2005
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemiaClaire N Harrison, Peter J Campbell, Georgina Buck, et al.
Blood|May 25, 2013
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyDavid M Ross, Susan Branford, John F Seymour, et al.
British Journal of Haematology|May 28, 2020
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemiaIng S Tiong, Richard Dillon, Adam Ivey, et al.
Blood|May 27, 2014
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineSusan Branford, David T Yeung, Wendy T Parker, et al.
Blood|August 5, 2024
Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND studyDavid T Yeung, Naranie Shanmuganathan, John Reynolds, et al.
Leukemia|October 14, 2018
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cellsDavid M Ross, Ilaria S Pagani, Naranie Shanmuganathan, et al.
British Journal of Haematology|December 23, 2025
The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemiaDavid T Yeung, Andrew P Grigg, John Reynolds, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Haematologica|October 5, 2023
Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1Howland E Crosswell, Ann S LaCasce, Nancy L Bartlett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2022
Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration CohortsPaul M Barr, Alessandra Tedeschi, William G Wierda, et al.
Pathology|March 6, 2021
Myeloid somatic mutation panel testing in myeloproliferative neoplasmsDavid M Ross, Candice Thomson, Nada Hamad, et al.
The New England Journal of Medicine|July 8, 2005
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemiaClaire N Harrison, Peter J Campbell, Georgina Buck, et al.
Blood|May 25, 2013
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyDavid M Ross, Susan Branford, John F Seymour, et al.
British Journal of Haematology|May 28, 2020
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemiaIng S Tiong, Richard Dillon, Adam Ivey, et al.
Blood|May 27, 2014
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineSusan Branford, David T Yeung, Wendy T Parker, et al.
Blood|August 5, 2024
Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND studyDavid T Yeung, Naranie Shanmuganathan, John Reynolds, et al.
Leukemia|October 14, 2018
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cellsDavid M Ross, Ilaria S Pagani, Naranie Shanmuganathan, et al.
British Journal of Haematology|December 23, 2025
The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemiaDavid T Yeung, Andrew P Grigg, John Reynolds, et al.
Pageof 4